drugset / Trial / NCT01784068
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NaSingle-groupOpen-labelOther
Summary
The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment
Timeline
- Start
- 2013-03-19
- Primary completion
- 2016-05-31
- Completion
- 2025-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nilotinib | Small molecule | 300 mg | — |
| Subject | Nilotinib | Small molecule | 400 mg | — |